T Cell News and Research

Latest T Cell News and Research

Advanced breast cancer drug appears effective on multiple targets

An experimental breast cancer drug that simultaneously attacks five tumor targets has halted progression of the disease in a clinical trial for patients with advanced disease.

18 May 2005

Researchers prevent post-traumatic brain damage using experimental drug

In animal studies, researchers from Georgetown University Medical Center have shown how traumatic brain injury leads to loss of brain function - and found that an experimental drug can stop the damage and promote recovery.

18 May 2005

Routine, inexpensive blood test sharpens heart disease risk predictions

Routine measurements of white blood cell counts that provide a ratio of neutrophils to lymphocytes may offer a simple and low-cost way to refine predictions of heart attack or death, according to a new study in the May 17, 2005, issue of the Journal of the American College of Cardiology.

18 May 2005

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

Nutrition gene key in regulating immune system

A gene that signals a yeast cell to make bread rise and mice to eat a better diet also helps selectively silence the immune system, researchers have found.

18 May 2005

Unrestrained retina too much of a good thing

When primitive nerve cells begin forming an eye in the mouse embryo, they are programmed to build a retina. But the ability to see depends upon connecting the retina to the brain via the optic nerve. Unless these embryonic cells are given the right cue at the right time, they mistakenly form a huge eye that consists entirely of retina and lacks the optic nerve.

18 May 2005

Zevalin safe and effective for non-Hogdkin's lymphoma patients

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.

17 May 2005

Tumor vasculature has become an attractive target in the treatment of cancer.

Treatment with a protein fused to an antibody in tumor-bearing mice led to coagulation of the blood within the tumor blood vessels, tumor tissue death, and tumor growth delay, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.

17 May 2005

Scientists have uncovered a new method the immune system uses to label foreign invaders as targets to be attacked

Researchers showed that the immune system can brand foreign proteins by chemically modifying their structure, and that these modifications increased the chances that cells known as lymphocytes would recognize the trespassers and attack them.

17 May 2005

Lower doses of chemo just as effective in childhood cancers

In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.

17 May 2005

New drug combination prevents breast cancer growth pre-surgery

A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs.

17 May 2005

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.

17 May 2005

Researchers create the first mouse model that develops a lymphoma the same way that humans do

This advancement has the potential to significantly speed the development of new, improved therapies for diffuse large B cell lymphoma (DLBCL), the most common type of human B cell lymphoma. Human B cell lymphomas cause 85 percent of non-Hodgkin's lymphomas, the sixth leading cause of cancer deaths in the United States.

17 May 2005

SU11248 drug show promise against neuroendocrine tumors-stubborn cancers that respond poorly to chemotherapy

A unique, targeted anti-cancer drug appears to show promise against neuroendocrine tumors-stubborn cancers that have traditionally responded poorly to chemotherapy, according to research findings announced at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2005

Drugs that block the enzyme Odc prevent the onset of cancers

The drug DFMO prevents cancer in laboratory models of lymphoma but fails to kill existing cancerous cells that have lost the ability to self-destruct, according to investigators at St. Jude Children's Research Hospital.

16 May 2005

Statin chemoprevention with minimal surveillance could prevent 96 percent of colon cancers

Ulcerative colitis affects about one out of every 2,000 Americans, and after living with the disease for 30 years, nearly 22 percent of those people will develop colon cancer.

16 May 2005

Scientists discover how excess body fat can lead to the onset of diabetes

One out of 12 people in the western world suffers from type 2 (adult onset) diabetes. Worldwide, 150 million people are diabetic and their numbers are expected to double in the next 20 years, a result of the growing obesity epidemic. Yet, the reasons for the strong correlation between excess body fat and diabetes have been puzzling researchers.

16 May 2005

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).

16 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005